AngioVac Removal of an Isolated Infected Pulmonary Valve Papillary Fibroelastoma

Abstract

The AngioVac (Angiodynamics) system is indicated for the removal of right-sided venous soft thrombi and emboli. This is the first report that demonstrates the AngioVac system can be extended to the extraction of right-sided cardiac tumors, in the current case, a pulmonary valve papillary fibroelastoma infected with Streptococcus salivarius and Rothia species. ( Level of Difficulty: Advanced. )

Percutaneous transeptal mitral valve endocarditis debulking with AngioVac aspiration system

“…Angiovac percutaneous vacuum-assisted aspiration system has been successfully utilized to aspirate right sided (atrial, tricuspid valve or vena cava) vegetations, pulmonic valve vegetations, right atrial masses, vena cava thrombus, thrombus/vegetation of cardiac implantable electronic devices, and for aspiration of thoracic aortic mass. [4][5][6][7][8] Other case report and series of patients describing novel and unique use of AngioVac aspiration system in various patient subset ie; pregnant, congenital heart disease, inferior vena cava filter thrombosis and cancer related thrombosis are further listed in Table 1. 9,10 While there are no official guidelines for intended use, it is generally reserved for patients who are inoperable or at high/prohibitive surgical risk.…”

Percutaneous Aspiration (AngioVac) of a Mitral Valve Vegetation followed by a Transcatheter Mitral Valve-in-Valve Intervention

“…In patients with high surgical risk, a minimally invasive technique that employs the AngioVac transcatheter aspiration system (Angiodynamics) is increasingly being used to debulk right-sided valve vegetations, thrombi, or tumors, with the goal of reducing the bacterial or embolic burden to temporize the acute illness. 5 , 6 , 7 The AngioVac system is based on an extracorporeal circuit in a veno-venous configuration, and the system is rarely used in the left heart. 8 We describe the novel use of simultaneous AngioVac evacuation and transcatheter MViV in the same procedure.…”